The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Recently, we reported the phase II portion of the adaptive phase II/III PANAMO trial exploring potential benefit and safety of selectively blocking C5a with the monoclonal antibody vilobelimab (IFX‐1) in patients with severe coronavirus disease 2019 (COVID‐19). The potent anaphylatoxin C5a attracts...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlaar, Alexander P. J., Lim, Endry H. T., de Bruin, Sanne, Rückinger, Simon, Pilz, Korinna, Brouwer, Matthijs C., Guo, Ren‐Feng, Heunks, Leo M. A., Busch, Matthias H., van Paassen, Pieter, Riedemann, Niels C., van de Beek, Diederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010279/
https://www.ncbi.nlm.nih.gov/pubmed/35029045
http://dx.doi.org/10.1111/cts.13213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010279/
https://www.ncbi.nlm.nih.gov/pubmed/35029045
http://dx.doi.org/10.1111/cts.13213

Ejemplares similares